Cynata Therapeutics Limited (CYP.XA)
Cboe AU · AUD
A$0.011 (+0.00%) as of
Key statistics
- EPS (TTM)
- -0.0280
- 52-week range
- 0.0100 – 0.4200
- Beta
- 1.12
- Revenue (TTM)
- 1.71M
- Profit margin
- 0.00%
- Volume
- 995.00
About Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia. The company develops CYP-004, an iPSC-derived mesenchymal stem cell (MSC) product candidate for intra-articular injection that has completed Phase 3 clinical trial for the treatment of osteoarthritis; CYP-001, an iPSC-derived MSC product candidate for intravenous use that is in a Phase 1/2 clinical trial for NEREID kidney transplantation; and CYP-006TK, an iPSC-derived MSC topical wound dressing product candidate that completed a Phase 1 trial for the treatment of diabetic foot ulcer. It is also developing pre-clinical pipeline products for asthma, cancer, cardiovascular, sepsis, critical limb ischemia, and idiopathic pulmonary fibrosis indications. The company has a strategic partnership agreement with FUJIFILM Corporation, as well as partnerships with the University of Sydney and Leiden University Medical Center. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
- Headquarters
- Cremorne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.